Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.

Louw, C; Williams, Z; Venter, L; Leichtl, S; Schmid-Wirlitsch, C; Bredenbroker, D; Bardin, P G

Louw, C; Williams, Z; Venter, L; Leichtl, S; Schmid-Wirlitsch, C; Bredenbroker, D; Bardin, P G.

Affiliation

Louw C; Internal Medicine, Lung and Allergy Unit, University of Stellenbosch, School of Medicine, Cape Town, South Africa.

Respiration ; 74(4): 411-7, 2007.

Article in En | MEDLINE | ID: mdl-16954654

Subject(s)

Allergens/adverse effects; Aminopyridines/therapeutic use; Benzamides/therapeutic use; Bronchial Hyperreactivity/drug therapy; Phosphodiesterase Inhibitors/therapeutic use; Administration, Oral; Adolescent; Adult; Aminopyridines/administration & dosage; Benzamides/administration & dosage; Bronchial Hyperreactivity/chemically induced; Bronchial Hyperreactivity/physiopathology; Bronchial Provocation Tests/adverse effects; Cross-Over Studies; Cyclopropanes/administration & dosage; Cyclopropanes/therapeutic use; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Forced Expiratory Volume/drug effects; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors/administration & dosage; Pilot Projects; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Phosphodiesterase Inhibitors / Benzamides / Allergens / Bronchial Hyperreactivity / Aminopyridines Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Humans / Male / Middle aged Language: En Journal: Respiration Year: 2007 Document type: Article Affiliation country: South Africa

Search on Google

Add to My VHL

XML

PubMed Links